Perry Capital Partners

Sharebite, Inc. is a meal benefits platform based in New York, established in 2014, that focuses on enhancing employee engagement through food ordering and delivery services. The platform enables users to browse and order from a wide selection of restaurant menus, facilitating team orders and centralized meal allowances tailored for modern workplaces. Sharebite's corporate clients span various industries, including financial services, technology, legal, and entertainment. A distinctive feature of the platform is its commitment to social responsibility; every transaction contributes to local hunger relief efforts through partnerships with organizations like Feeding America and City Harvest. This mission-driven approach not only supports employees' dining needs but also fosters community impact, enabling users to support small businesses and contribute to societal well-being.

Loadsmart operates an online platform designed to streamline the process of booking trucks for shippers and carriers. The company's technology enables users to obtain real-time bookable rates instantly, facilitating efficient interactions between shippers and carriers. Loadsmart was founded in 2014 by Felipe Capella and Ricardo Salgado and is headquartered in Chicago, Illinois, with an additional office in New York, New York.

Loadsmart operates an online platform designed to streamline the process of booking trucks for shippers and carriers. The company's technology enables users to obtain real-time bookable rates instantly, facilitating efficient interactions between shippers and carriers. Loadsmart was founded in 2014 by Felipe Capella and Ricardo Salgado and is headquartered in Chicago, Illinois, with an additional office in New York, New York.

Capital Factors is an innovative and leading provider of factoring, credit protection, accounts receivable collection services.

Palatin Technologies is a biopharmaceutical company focused on developing targeted, receptor-specific peptide therapeutics to address significant unmet medical needs. Based in Cranbury, New Jersey, the company’s lead product is Vyleesi, a melanocortin receptor agonist designed for the treatment of premenopausal women with hypoactive sexual desire disorder. Palatin is also advancing several other candidates, including oral PL8177, which targets inflammatory bowel diseases, and systemic PL8177, aimed at treating non-infectious uveitis and COVID-19. Additionally, the company is developing PL9643 for anti-inflammatory ocular conditions like dry eye disease, as well as PL3994 and PL5028, which target cardiovascular and fibrotic diseases. Their research emphasizes the modulation of melanocortin and natriuretic peptide receptor systems to resolve inflammation and facilitate tissue healing, with applications extending to various conditions, including obesity, erectile dysfunction, and pulmonary diseases.